Inhibitory effect of recombinant receptor activator of nuclear factor kappaB protein on bone loss in ovariectomized mice / 中国骨伤
China Journal of Orthopaedics and Traumatology
;
(12): 414-418, 2013.
Article
in Chinese
| WPRIM
| ID: wpr-353109
ABSTRACT
<p><b>OBJECTIVE</b>To compare inhibitory effects of recombinant receptor activator of nuclear factor kappaB protein with bisphosphonate treatment (ALN) on osteoclasts activity and bone loss in ovariectomized mice.</p><p><b>METHODS</b>Twenty-four female KM mice were ovariectomized bilaterally and treated with recombinant receptor activator of nuclear factor kappaB protein, alendronate, or PBS. Twelve weeks later, body weight, biochemical markers of bone metabolism, Micro CT scan and bone morphology were examined.</p><p><b>RESULTS</b>After 12 weeks administration, the Micro CT scan and bone morphology values of each group were as follow. The control group BMD (92.600 +/- 14.319) mg/cc, Tb.Th (0.094 +/- 0.011) mm, Tb.Sp (0.455 +/- 0.124) mm, BVF 0.192 +/- 0.023, SMI 1.388 +/- 0.328; the recombinant receptor activator of nuclear factor kappaB protein group BMD (133.050 +/- 13.022) mg/cc, Tb.Th (0.098 +/- 0.009) mm, Tb.Sp (0.365 +/- 0.105) mm,BVF (0.291 +/- 0.025)%, SMI 0.661 +/- 0.384; the ALN group BMD(128.013 +/- 16.040) mg/cc, Tb.Th (0.097 +/- 0.011) mm, Tb.Sp (0.376 +/- 0.104) mm, BVF 0.281 +/- 0.024, SMI 0.753 +/- 0.307. In the ovariectomized mice experiments, both recombinant receptor activator of nuclear factor kappaB protein and ALN significantly inhibited ovariectomy-induced bone loss. Compared to the control group (PBS), the recombinant receptor activator of nuclear factor kappaB protein group showed increased distal femur BMD and decreased trabecular spacing (Tb.Sp), whereas the control group had significantly decreased distal femur BMD, significantly decreased Tb.Th, and increased Tb.Sp. There was a significant difference in bone volume fraction among the groups. The TRAP-positive osteoclasts in distal femur bone slices were nearly complete inhibited for Recombinant receptor activator of nuclear factor kappaB protein group and alendronate group.</p><p><b>CONCLUSION</b>In vivo, recombinant receptor activator of nuclear factor kappaB protein effectively inhibits the activity of osteoclasts and the resulting bone loss, which has a similar effect as alendronate.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Osteoporosis
/
Diagnostic Imaging
/
Radiography
/
Ovariectomy
/
Bone Density
/
Therapeutic Uses
/
Diphosphonates
/
Drug Therapy
/
Receptor Activator of Nuclear Factor-kappa B
Type of study:
Diagnostic study
Limits:
Animals
Language:
Chinese
Journal:
China Journal of Orthopaedics and Traumatology
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS